文献速递胸部外周血管介入CTDSA

持续性肺动静脉畸形再治疗的中期疗效与影响因素

Retreatment of persistent pulmonary arteriovenous malformations: factors associated with technical success and durable occlusion.
PubMed 文献 · Clin Radiol · 2026-07-21

该单中心回顾性研究纳入19例持续性肺动静脉畸形患者的24次再治疗,评估初次栓塞后再治疗的长期闭塞结局。再治疗技术成功率为88%,中位随访31个月的总持久闭塞率为71%。再治疗时对畸形核心进行栓塞与持久闭塞显著相关,且核心定向再治疗者全部保持闭塞。

要点

  • 对持续存在的肺动静脉畸形,再治疗中有机会应尽量栓塞畸形核心,本研究中该策略持久闭塞率达100%。
  • 再治疗后需关注两种失败机制:原栓塞材料内持续血流或再通(63%)、额外供血动脉再灌注(29%)。
  • 单纯型或囊状肺动静脉畸形并非持久闭塞的独立预测因素,复杂/非囊状病灶同样可尝试积极再治疗。

核心结论

  • 持续性肺动静脉畸形再治疗可在中期随访获得较高技术成功率(88%)和持久闭塞率(71%)。
  • 再治疗时栓塞畸形核心与持久闭塞显著相关(p=0.005),本研究中核心定向再治疗者全部保持闭塞。
  • 畸形是否单纯、是否囊状、既往是否再通/持续血流或再灌注以及栓塞材料类型均与持久闭塞无显著相关。

研究设计与样本

  • 单中心回顾性研究,纳入19例患者共24次持续性肺动静脉畸形再治疗操作。
  • 中位年龄59岁,范围9-71岁;再次治疗成功与否由随访影像评估。

关键影像表现/征象

  • 初次治疗后持续血流或原栓塞材料内再通见于15/24(63%)。
  • 通过募集额外供血动脉的再灌注见于7/24(29%)。
  • 同时存在再通/持续血流和额外供血动脉再灌注者见于2/24(8%)。

诊断标准与关键数值

  • 再治疗技术成功率为88%。
  • 总体持久长期闭塞率为71%,累计中位随访31个月。
  • 再治疗时经原栓塞材料或募集血管进入畸形核心进行栓塞者占11/24(46%),该组全部在随访中保持闭塞。
  • 畸形核心定向再治疗与持久闭塞相关(p=0.005)。
  • 单纯型(p=0.68)、囊状(p=0.68)、非纤毛弹簧圈(p=0.26)、纤毛弹簧圈(p=0.36)、栓塞栓子(p=0.54)、既往再通/持续血流(p=0.68)及既往再灌注(p=0.54)均与持久闭塞无显著相关。

临床应用与阅片要点

  • 随访发现持续性肺动静脉畸形时,应评估血流再通/持续和额外供血动脉再灌注两种常见失败机制。
  • 再次栓塞应优先尝试进入畸形核心,即使需穿过原栓塞材料或经募集血管进入。
  • 单纯型或囊状形态不应成为再治疗决策中减弱积极性的理由。

局限性

  • 单中心回顾性设计。
  • 样本量为19例患者共24次再治疗操作,样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To evaluate factors that contribute to successful retreatment of persistent Pulmonary Arteriovenous Malformations (PAVMs) after initial embolization, focusing on long-term occlusion outcomes.

MATERIALS AND METHODS: This study reviewed consecutive treatments for persistent PAVMs re-treated at a single institution. The success of repeat treatment was assessed on follow-up imaging.

RESULTS: Twenty-four retreatment procedures in 19 patients were included (median age 59, range 9-71). Most PAVMs were simple (71%) rather than complex (29%), and saccular (71%) rather than non-saccular (29%). PAVMs were primarily treated with coils (88%) rather than plug or coil and plug (12%). The nidus was primarily treated in only 4/24 (17%). Primary treatment persistent flow or recanalization through the existing embolization material was seen in 15/24 (63%), reperfusion via recruitment of additional feeding arteries in 7/24 (29%), and both in 2/24 (8%). Retreatment technical success was 88%. Re-embolization into the nidus either through the existing embolic material or via a recruited vessel was performed in 11/24 (46%), and all remained occluded throughout follow-up. Overall durable long-term occlusion was seen in 71% with cumulative median follow-up of 31 months. Durable PAVM occlusion was associated with re-treatment of the nidus (p = 0.005), but not simple (p = 0.68) or saccular PAVM (p = 0.68), retreatment with non-fibered coils (p = 0.26), fibered coils (p = 0.36) or plug (p = 0.54), prior recanalization/persistence (p = 0.68), or prior reperfusion (p = 0.54). No major procedural complications occurred.

CONCLUSION: Retreatment of persistent PAVMs led to high immediate technical success (88%) and durable occlusion (71%) on mid-term follow-up. Nidus-directed retreatment was associated with 100% durable occlusion.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Pudar, Lindquist, Sterbis, et al. Retreatment of persistent pulmonary arteriovenous malformations: factors associated with technical success and durable occlusion. Clin Radiol. 2026. PMID: 42585690. doi:10.1016/j.crad.2026.107440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。